Prestige Consumer Healthcare draws $95.0 million term loan to fund LaCorium acquisition

Prestige Consumer Healthcare Inc. (NYSE: PBH) borrowed $95,000,000 on July 1, 2026 under an amendment to its term loan credit agreement, according to a Form 8-K filed July 6, 2026. The borrower is its wholly owned subsidiary, Prestige Brands, Inc. The company is based in Tarrytown, New York. The borrowing was used to finance part of the LaCorium Acquisition, together with fees and expenses, and the acquisition closed on the same day.

The amendment

The company and Prestige Brands signed the amendment on July 1, 2026, which the 8-K calls the Closing Date. Certain other subsidiaries of the company are guarantors under the Term Loan Credit Agreement. The amendment lets the borrower take additional term loans of up to $95.0 million, which it may use to finance in part the acquisition of five Australian companies: LaCorium Health Australia Pty Limited, Stantail Trading Pty Limited, Stantail International Pty Limited, Brands Worldwide Holdings I.P. Pty Limited and Laderma Holdings Pty Limited. Fees and expenses of that acquisition are also covered.

The 8-K reports the borrowing under Item 2.03, the item for the creation of a direct financial obligation. On the Closing Date the borrower drew the full $95,000,000. The company says a copy of the amendment will be filed as an exhibit to its quarterly report on Form 10-Q for the quarter ended June 30, 2026, so the full terms are not in the 8-K itself.

The lenders and arrangers

Citibank, N.A. is the administrative agent under the Term Loan Credit Agreement. The 8-K names Citibank, N.A., Barclays Bank PLC, Morgan Stanley Senior Funding Inc., Goldman Sachs Bank USA and RBC Capital Markets as joint lead arrangers and joint bookrunners. The lenders are the parties to the agreement and are not listed by name in the 8-K. The 8-K names no separate counsel for the company, the borrower or the lenders.

The senior notes offering

Under Item 7.01, the company reports two press releases. The first, dated June 30, 2026, announced the start of a private offering of $400,000,000 of senior unsecured notes due 2034. The second, dated July 6, 2026, announced the completion of the LaCorium Acquisition and the pricing of that offering. Both are furnished as exhibits, and the 8-K text does not give the coupon, the price or the names of the initial purchasers.

A private offering is a sale of securities that is not registered with the SEC. Senior unsecured notes are debt that is not backed by specific collateral.

The deal size

The company's annual report for the fiscal year ended March 31, 2026 says it had entered into a definitive agreement to acquire LaCorium Health for approximately $150.0 million, and expected the deal to close in the second quarter of fiscal 2027. The 8-K shows the acquisition closing on July 1, 2026, which fits that window. The term loan amendment covers $95.0 million of that price, in part.

That leaves a gap the 8-K does not close. The text says the amendment finances the acquisition in part, and it does not say how the rest of the purchase price was paid.

The business

The annual report describes Prestige as a maker and seller of brand name over-the-counter health and personal care products. Its common stock is listed on the New York Stock Exchange under the symbol PBH.

What the filings leave open

The 8-K gives the amount, the agent and the arrangers, but not the interest rate on the new borrowing. It also does not give the post-closing debt total, the amount of the notes that will be used for the acquisition, or the timing of the amendment's filing beyond the 10-Q. The 8-K therefore does not show the company's total debt after the acquisition or how much of the $150.0 million price the notes will cover.

Report an error

Companies in this story

PBHPrestige Consumer Healthcare Inc.NYSE · United StatesOpen the starter desk